Zero Candida Technologies Gears Up for Investor Conference with DTC Eligibility Announcement
On August 5, 2025, Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2), a pioneering FemTech medical device company, announced that its shares are now eligible for Depository Trust Company (DTC) electronic clearing and settlement services. This eligibility marks a substantial advancement in the company's strategy to enhance access and liquidity for U.S. investors.
Eli Ben Haroosh, the Founder and CEO of Zero Candida, expressed excitement regarding this development, stating, “Achieving DTC eligibility is a key milestone in our capital markets strategy. It improves trading efficiency and enhances liquidity while making it easier for U.S. investors to access our stock.”
The company is currently set to present at the OTCQB Venture Virtual Investor Conference, which will take place on August 7, 2025. This platform is designed to provide publicly traded companies with the opportunity to engage directly with investors, allowing for a seamless presentation experience. By participating in this event, Zero Candida aims to broaden its reach among both institutional and retail investors.
DTC eligibility is expected to greatly benefit investors by streamlining the clearing and settlement process of their shares, thus reducing transaction costs. This development is crucial for investors, particularly institutions, that need DTC eligibility for their investment parameters. By decreasing settlement times and improving overall access, Zero Candida is committed to enhancing its market position while unlocking potential value through its AI-driven medical technologies.
The upcoming virtual conference is part of a strategic move by Zero Candida to engage more effectively with the investment community. This initiative allows for real-time interaction between the company and potential investors, further matched through video content and targeted one-on-one meetings to deepen understanding of the company’s vision and innovations.
Zero Candida Technologies is at the forefront of addressing significant gaps in women's health with its revolutionary tampon-like device, which utilizes artificial intelligence and therapeutic blue light to combat Candida fungus. Currently, Vulvo-Vaginal Candidiasis (VVC) affects around 75% of women globally, and existing treatments often fall short, particularly for recurrent cases which resist conventional drug treatments. The company's device boasts an impressive 99.999% success rate in clinical trials.
Currently preparing for clinical trials following successful safety tests in large animals, the company is fully committed to navigating the de novo regulatory pathway. Moreover, they have established partnerships with leading hospitals in Europe and Israel while expanding their patent portfolio to secure their innovative approach.
With the market for VVC treatments projected to surpass USD $2 billion in the next five years, Zero Candida Technologies merges advanced medicine with technology-driven diagnostics to improve healthcare access for women globally. For those interested in learning more about their initiatives, visit www.zero-candida.com.
In conclusion, as Zero Candida Technologies embarks on this new chapter with DTC eligibility, the company remains determined to provide cutting-edge solutions in women's healthcare while enhancing its visibility and investor relationships through strategic platforms like the OTCQB Venture Virtual Investor Conference.
Eli Ben Haroosh, the Founder and CEO of Zero Candida, expressed excitement regarding this development, stating, “Achieving DTC eligibility is a key milestone in our capital markets strategy. It improves trading efficiency and enhances liquidity while making it easier for U.S. investors to access our stock.”
The company is currently set to present at the OTCQB Venture Virtual Investor Conference, which will take place on August 7, 2025. This platform is designed to provide publicly traded companies with the opportunity to engage directly with investors, allowing for a seamless presentation experience. By participating in this event, Zero Candida aims to broaden its reach among both institutional and retail investors.
DTC eligibility is expected to greatly benefit investors by streamlining the clearing and settlement process of their shares, thus reducing transaction costs. This development is crucial for investors, particularly institutions, that need DTC eligibility for their investment parameters. By decreasing settlement times and improving overall access, Zero Candida is committed to enhancing its market position while unlocking potential value through its AI-driven medical technologies.
The upcoming virtual conference is part of a strategic move by Zero Candida to engage more effectively with the investment community. This initiative allows for real-time interaction between the company and potential investors, further matched through video content and targeted one-on-one meetings to deepen understanding of the company’s vision and innovations.
Zero Candida Technologies is at the forefront of addressing significant gaps in women's health with its revolutionary tampon-like device, which utilizes artificial intelligence and therapeutic blue light to combat Candida fungus. Currently, Vulvo-Vaginal Candidiasis (VVC) affects around 75% of women globally, and existing treatments often fall short, particularly for recurrent cases which resist conventional drug treatments. The company's device boasts an impressive 99.999% success rate in clinical trials.
Currently preparing for clinical trials following successful safety tests in large animals, the company is fully committed to navigating the de novo regulatory pathway. Moreover, they have established partnerships with leading hospitals in Europe and Israel while expanding their patent portfolio to secure their innovative approach.
With the market for VVC treatments projected to surpass USD $2 billion in the next five years, Zero Candida Technologies merges advanced medicine with technology-driven diagnostics to improve healthcare access for women globally. For those interested in learning more about their initiatives, visit www.zero-candida.com.
In conclusion, as Zero Candida Technologies embarks on this new chapter with DTC eligibility, the company remains determined to provide cutting-edge solutions in women's healthcare while enhancing its visibility and investor relationships through strategic platforms like the OTCQB Venture Virtual Investor Conference.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.